DefinitionThis section has been translated automatically.
Virustatic. Inhibitor of HIV protease. Prodrug of Amprenavir.
IndicationThis section has been translated automatically.
Antiretroviral combination therapy for the treatment of HIV-1 infection in experienced patients, in particular those pre-treated with protease inhibitors.
Notice!
Consideration of the viral resistance pattern and pretreatment of the patient, especially with other protease inhibitors!You might also be interested in
Pregnancy/nursing periodThis section has been translated automatically.
Contraindicated during pregnancy and lactation (insufficient data available).
Dosage and method of useThis section has been translated automatically.
- Pat. > 18 y.: Monotherapy: 2 times/day 1400 mg p.o. (not recommended for pretreated patients).
- Combination with ritonavir: fosamprenavir: 2 times/day 700 mg p.o. + ritonavir: 2 times/day 100 mg p.o. Alternatively: fosamprenavir 1 time / day 1400 mg p.o. and ritonavir 1 time / day 200 mg p.o.
Undesirable effectsThis section has been translated automatically.
Often cutaneous NW like maculopapular exanthema. Occasionally gastrointestinal symptoms (diarrhoea, vomiting), headaches.
InteractionsThis section has been translated automatically.
Caution in combination with Lopinavir: decrease of the plasma levels of both substances (AUC, Cmin)!
Notice! Severe drug interactions can potentially occur with drugs such as amiodarone, lidocaine (systemic use), tricyclic antidepressants, quinidine.
ContraindicationThis section has been translated automatically.
Hypersensitivity to the substance, comedication with benzodiazepines (midazolam, triazolam), ergotamine derivatives, cisapride, neuroleptics.
PreparationsThis section has been translated automatically.
Telzir
Prof. Dr. med. Peter Altmeyer